Patents by Inventor Liangxing Wu

Liangxing Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200283423
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: April 17, 2020
    Publication date: September 10, 2020
    Inventors: Zhiyong Yu, Liangxing Wu, Wenqing Yao
  • Publication number: 20200277309
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: March 5, 2020
    Publication date: September 3, 2020
    Inventors: Liangxing Wu, Kaijiong Xiao, Wenqing Yao
  • Publication number: 20200255424
    Abstract: Disclosed are compounds of Formula (I?), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: April 23, 2020
    Publication date: August 13, 2020
    Inventors: Liangxing Wu, Jingwei Li, Wenqing Yao
  • Patent number: 10738048
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: August 11, 2020
    Assignee: Incyte Corporation
    Inventors: Liang Lu, Liangxing Wu, Ding-Quan Qian, Wenqing Yao
  • Patent number: 10717737
    Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: July 21, 2020
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Chunhong He, Wenqing Yao, Fenglei Zhang
  • Publication number: 20200199131
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting ALK2 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with ALK2 activity such as cancer.
    Type: Application
    Filed: December 19, 2019
    Publication date: June 25, 2020
    Inventors: Jun Pan, Jeremy Roach, Song Mei, Chunhong He, Liangxing Wu, Wenqing Yao
  • Publication number: 20200181077
    Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: November 20, 2019
    Publication date: June 11, 2020
    Applicant: Incyte Corporation
    Inventors: Liangxing Wu, Chunhong He, Ding-Quan Qian, Bo Shen, Wenqing Yao
  • Publication number: 20200181126
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: February 4, 2020
    Publication date: June 11, 2020
    Inventors: Liang Lu, Ding-Quan Qian, Liangxing Wu, Wenqing Yao
  • Patent number: 10676457
    Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: June 9, 2020
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Wenqing Yao
  • Publication number: 20200172541
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: February 4, 2020
    Publication date: June 4, 2020
    Inventors: Zhenwu Li, Liangxing Wu, Wenqing Yao
  • Publication number: 20200172533
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: February 4, 2020
    Publication date: June 4, 2020
    Inventors: Liangxing Wu, Fenglei Zhang, Song Mei, Wenqing Yao
  • Patent number: 10669271
    Abstract: Disclosed are compounds of Formula (I?), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: June 2, 2020
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Jingwei Li, Wenqing Yao
  • Patent number: 10640503
    Abstract: The present invention is directed to imidazo[1,5-a]pyridine and imidazo[1,5-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: May 5, 2020
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Leah C. Konkol, Neil Lajkiewicz, Liang Lu, Meizhong Xu, Wenqing Yao, Zhiyong Yu, Colin Zhang, Chunhong He
  • Patent number: 10632126
    Abstract: The present disclosure relates to bicyclic heterocycles of Formula (I?), and pharmaceutical compositions of the same, that are inhibitors of the FGFR3 and/or FGFR4 enzyme and are useful in the treatment of FGFR-associated diseases.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: April 28, 2020
    Assignee: Incyte Corporation
    Inventors: Alexander Sokolsky, Liangxing Wu, Wenqing Yao
  • Publication number: 20200115378
    Abstract: The present application provides dihydropyrido[2,3-d]pyrimidone inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: October 10, 2019
    Publication date: April 16, 2020
    Inventors: Alexander Sokolsky, Liangxing Wu, Wenqing Yao
  • Patent number: 10618916
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: April 14, 2020
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Kaijiong Xiao, Wenqing Yao
  • Publication number: 20200095244
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Application
    Filed: September 10, 2019
    Publication date: March 26, 2020
    Inventors: Yaping Sun, Liang Lu, Wenqing Yao, Jincong Zhuo, Liangxing Wu, Meizhong Xu, Ding-Quan Qian, Chunhong He, Fenglei Zhang
  • Publication number: 20200095250
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting ALK2 activity and/or FGFR activity, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with ALK2 activity and/or FGFR activity, such as cancer.
    Type: Application
    Filed: September 24, 2019
    Publication date: March 26, 2020
    Inventors: Oleg Vechorkin, Minh Nguyen, Chao Qi, Anlai Wang, Liangxing Wu, Wenqing Yao, Peng Zhao
  • Patent number: 10556908
    Abstract: The present invention is directed to imidazo[1,2-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: February 11, 2020
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Joel R. Courter, Chunhong He, Jingwei Li, Liang Lu, Yaping Sun, Xiaozhao Wang, Wenqing Yao, Colin Zhang, Jincong Zhuo
  • Publication number: 20200039994
    Abstract: The present application provides heteroaryl amide compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Application
    Filed: July 31, 2019
    Publication date: February 6, 2020
    Inventors: Liangxing Wu, Neil Lajkiewicz, Wenqing Yao